Biotech2k
Biotech Investor, AI-Driven Drug Discovery
Crescent Biopharma is a speculative bet that could be a huge winner if its PD-1/VEGF antibody, similar to Summit Therapeutics', shows data as good or better. The program is only in phase 1, but the company trades at 5% of Summit's market cap and has a broader pipeline, which justifies risking a little. x.comÂ
Summit Therapeutics' leaders bought at the lows, a strong signal ahead of the November 14 FDA decision date for ivonescimab. Co-CEO Robert Duggan bought 3.81M shares twice at $13.12, about $100M, the same week Summit pulled a $500M stock offering, choosing personal cash over dilution. Phase 3 HARMONi-6 showed ivonescimab cut the risk of death 34% versus tislelizumab combinations in first-line squamous NSCLC. A pennant breakout above $15.88 could run toward the $20s. x.com x.comÂ
Summit Therapeutics' two co-CEOs bought a massive $100M of stock at the lows, and insiders keep buying, a sign something is cooking. After a 30% fall over the past year the shares are cheap, and cheap is when to buy. x.com x.comÂ
Significant discounts to broader pharmaceutical industry valuations on projected 2031 earnings make some high-quality mid-cap biotech stocks attractive. Many have cleared Phase 3 trials or reached more advanced stages, and some may reach profitability without more capital, an advantage if financing tightens. Selling these stocks to chase speculative biotech or large pharma at historically elevated multiples makes little sense. x.comÂ
Summit Therapeutics' ivonescimab looks materially de-risked after beating Keytruda on overall survival. Partner Akeso said ivonescimab monotherapy showed a statistically significant survival benefit over Keytruda in PD-L1+ advanced lung cancer in China's Phase III HARMONi-2 trial, the first drug to do so head-to-head, answering the global HARMONi survival miss ahead of a November 14 FDA decision date. Insider buying, notably by Robert Duggan, and large short interest add to the setup. x.com … Show more
Small- and mid-cap biotech looks like one of healthcare's more asymmetric setups after a four-year bear market, as AI speeds drug discovery and Big Pharma faces a patent cliff. Over $300B of pharma revenue goes off patent in the next few years, M&A is already ramping hard as pharma hunts for assets, and many small and mid-cap names still trade at reasonable valuations, making them potential takeover targets. x.comÂ
Ionis is best avoided because major Phase 3 trials still hang over it, making it hard to size a meaningful position while controlling risk. Biotechs can drop 10-30% overnight on a negative read-through from another company's similar drug, with no chance to react, and a 1-2% position is mostly a waste of time. Biotech names are worth owning only once profitable, generating real cash and free of major Phase 3 risk. x.comÂ
